Price to Sales (P/S)
since 2005
Paying user area
Try for free
Vertex Pharmaceuticals Inc. pages available for free this week:
- Income Statement
- Statement of Comprehensive Income
- Cash Flow Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Long-term (Investment) Activity Ratios
- Price to FCFE (P/FCFE)
- Capital Asset Pricing Model (CAPM)
- Present Value of Free Cash Flow to Equity (FCFE)
- Return on Equity (ROE) since 2005
- Price to Operating Profit (P/OP) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Vertex Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Vertex Pharmaceuticals Inc., P/S, long-term trends, calculation
| P/S | = | Share price1, 2, 3 | ÷ | Sales per share1 | Sales per share1 | = | Revenues1 (in thousands) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 13, 2025 | = | ÷ | = | ÷ | |||||||
| Feb 15, 2024 | = | ÷ | = | ÷ | |||||||
| Feb 10, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 9, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 11, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 15, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 23, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 16, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 11, 2014 | = | ÷ | = | ÷ | |||||||
| Mar 1, 2013 | = | ÷ | = | ÷ | |||||||
| Feb 22, 2012 | = | ÷ | = | ÷ | |||||||
| Feb 17, 2011 | = | ÷ | = | ÷ | |||||||
| Feb 19, 2010 | = | ÷ | = | ÷ | |||||||
| Feb 17, 2009 | = | ÷ | = | ÷ | |||||||
| Feb 11, 2008 | = | ÷ | = | ÷ | |||||||
| Mar 1, 2007 | = | ÷ | = | ÷ | |||||||
| Mar 16, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Vertex Pharmaceuticals Inc. Annual Report.
- Share Price Trend
- The share price exhibited significant volatility over the observed period. It started at $39.49 in 2006, declined sharply to a low point around 2008 at $18.21, then showed gradual recovery and subsequent growth. From 2013 onward, the share price substantially increased, reaching $426.29 by 2023 and further rising to $462.58 in 2024. Despite some fluctuations, the overall trajectory from 2010 to 2024 is strongly upward, indicating increased market valuation and investor confidence.
- Sales Per Share
- Sales per share showed a mixed pattern in the early years, with some decreases noted between 2006 and 2010, dropping to as low as $0.51 in 2010. However, from 2010 onwards there is a marked and consistent increase in sales per share, accelerating notably after 2012. The figure rose from $6.71 in 2012 to $42.91 in 2025, reflecting a substantial growth in revenue generation capacity per share over time.
- Price-to-Sales Ratio (P/S)
- The price-to-sales ratio demonstrates considerable fluctuation consistent with the movements in share price and sales per share. Early in the timeline, the ratio was very high, peaking at 80.12 in 2010, suggesting that the share price was very high relative to sales at that time, possibly due to speculative trading or expectations unmet by actual sales. Post-2011, the P/S ratio declined significantly and stabilized, fluctuating mostly between 5 and 17, which reflects a more balanced valuation relative to sales. From about 2016 onwards, the P/S ratio remained relatively stable in a range between approximately 8 and 16, indicating a consistent market valuation in relation to company sales.
- Overall Insights
- The extensive growth in sales per share coupled with a rising share price indicates robust operational performance and growth in shareholder value over the long term. The early period's high P/S ratios may denote overvaluation or market uncertainty, while the subsequent normalization aligns with improved financial metrics and investor confidence. The data suggest that the company's market capitalization growth is supported by real increases in sales revenue rather than speculative factors alone.
Comparison to Competitors
Vertex Pharmaceuticals Inc., P/S, long-term trends, comparison to competitors
| Vertex Pharmaceuticals Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 13, 2025 | ||||||||||||
| Feb 15, 2024 | ||||||||||||
| Feb 10, 2023 | ||||||||||||
| Feb 9, 2022 | ||||||||||||
| Feb 11, 2021 | ||||||||||||
| Feb 13, 2020 | ||||||||||||
| Feb 13, 2019 | ||||||||||||
| Feb 15, 2018 | ||||||||||||
| Feb 23, 2017 | ||||||||||||
| Feb 16, 2016 | ||||||||||||
| Feb 13, 2015 | ||||||||||||
| Feb 11, 2014 | ||||||||||||
| Mar 1, 2013 | ||||||||||||
| Feb 22, 2012 | ||||||||||||
| Feb 17, 2011 | ||||||||||||
| Feb 19, 2010 | ||||||||||||
| Feb 17, 2009 | ||||||||||||
| Feb 11, 2008 | ||||||||||||
| Mar 1, 2007 | ||||||||||||
| Mar 16, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Vertex Pharmaceuticals Inc., P/S, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Vertex Pharmaceuticals Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 13, 2025 | ||
| Feb 15, 2024 | ||
| Feb 10, 2023 | ||
| Feb 9, 2022 | ||
| Feb 11, 2021 | ||
| Feb 13, 2020 | ||
| Feb 13, 2019 | ||
| Feb 15, 2018 | ||
| Feb 23, 2017 | ||
| Feb 16, 2016 | ||
| Feb 13, 2015 | ||
| Feb 11, 2014 | ||
| Mar 1, 2013 | ||
| Feb 22, 2012 | ||
| Feb 17, 2011 | ||
| Feb 19, 2010 | ||
| Feb 17, 2009 | ||
| Feb 11, 2008 | ||
| Mar 1, 2007 | ||
| Mar 16, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Vertex Pharmaceuticals Inc., P/S, long-term trends, comparison to industry (health care)
| Vertex Pharmaceuticals Inc. | Health Care | |
|---|---|---|
| Feb 13, 2025 | ||
| Feb 15, 2024 | ||
| Feb 10, 2023 | ||
| Feb 9, 2022 | ||
| Feb 11, 2021 | ||
| Feb 13, 2020 | ||
| Feb 13, 2019 | ||
| Feb 15, 2018 | ||
| Feb 23, 2017 | ||
| Feb 16, 2016 | ||
| Feb 13, 2015 | ||
| Feb 11, 2014 | ||
| Mar 1, 2013 | ||
| Feb 22, 2012 | ||
| Feb 17, 2011 | ||
| Feb 19, 2010 | ||
| Feb 17, 2009 | ||
| Feb 11, 2008 | ||
| Mar 1, 2007 | ||
| Mar 16, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).